Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM
| Status: | Archived |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | April 2009 |
| End Date: | September 2011 |
Effects of Pramlintide on Endogenous Production of VLDL-Triglyceride and Glucose in the Post Prandial State in Type 2 Diabetes Mellitus
Diabetes affects almost 21 million people in the United States. In this study we will test a
drug called Pramlintide(Symlin), and see how it works to lower blood sugar and fat levels
after a meal. Lowering high sugar levels and fat levels after a meal is very important in
the prevention of the problems that persons with type 2 diabetes often encounter. Hypothesis
is that Pramlintide will lower blood sugar and fat levels after a meal.
A well recognized and troublesome feature of diabetes management is the exacerbated post
prandial glucose elevations following a typical high fat meal. To date the mechanisms
driving this increased post prandial glycemia are unclear. Pramlintide is believed to
affect intermediary metabolism as well as nutrient absorption. The relative contributions
from altered absorption and metabolism to the observed post prandial reductions in plasma
glucose and TG concentrations remain uncertain, however. Combinations of radioactive and
stable isotope labeling techniques are able to quantify the relevant fluxes of glucose and
lipids in vivo in humans and are therefore able to provide quantitative answers to these
questions.
Aims:
1. To determine the effects of Pramlintide on reducing endogenous production of
very-low-density-lipoprotein (VLDL)-triglycerides(TG) following a high fat breakfast,
lunch and dinner in patients with type 2 diabetes mellitus (T2DM). A triple isotope
approach will be used to determine rate of appearance of (VLDL)-triglycerides following
breakfast, lunch and dinner.
2. To compare the relative roles of slowed glucose absorption and reduced endogenous
glucose production (glucagonstatic mechanism) in the glucose-lowering effects of
Pramlintide in the post prandial state in patients with T2DM.
We found this trial at
1
site
Click here to add this to my saved trials
